Background {#Sec1}
==========

Poland Syndrome (PS, MIM173800) is a congenital disorder of the pectoralis major muscle. PS patients present with pectoralis muscle agenesis/hypoplasia, more frequently on the right side. PS can be associated with a variable degree of ipsilateral thoracic and/or upper limb anomalies \[[@CR1], [@CR2]\]. Incidence of PS has been reported between 1/20,000 and 1/30,000 births with a higher prevalence in males \[[@CR3], [@CR4]\]. Today, PS etiopathogenesis is still unknown. One of the most common assumptions is that isolated pectoralis major muscle defects are included in the spectrum of anomalies postulated to result from disruption of blood supply in the embryonic subclavian and vertebral arteries \[[@CR5], [@CR6]\]. Alternatively, PS may be due to the involvement of genes regulating embryonic development of pectoral girdle \[[@CR7]\]. Familial recurrence was observed in about 10% of cases with different inheritance patterns including autosomal dominant with incomplete penetrance, autosomal recessive, and X-linked \[[@CR1]\]. The presence of different genes whose mutations may account for clinical differences among subgroups of patients and for the different inheritance patterns observed could be hypothesized. Two recently reported cases of de novo deletions contribute to support the genetic origin of PS and suggests the involvement of the deleted regions in PS pathogenesis. A deletion of chromosome 11q12.3 in monozygotic twins both affected by PS \[[@CR8]\] and a large deletion of chromosome 6q21-q22.1 in a patient with a complex phenotype mainly characterized by mental disability and PS \[[@CR9]\]. Genomic imbalances and copy number variants (CNV) represent a main source of genetic variation in humans and contribute to different congenital and neurodevelopmental defects \[[@CR10]--[@CR14]\]. However, the contribution of genomic imbalances to a broader number of PS patients has not been systematically studied. In this study, we performed karyotyping and array-CGH analysis of a large cohort of PS patients to discover novel chromosomal regions associated with this condition.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The present cohort comprises 120 patients with pectoralis muscle agenesis/hypoplasia, either isolated or with associated anomalies (clinical data are summarized in Table [1](#Tab1){ref-type="table"}). Control population (in-house controls) comprises 200 patients affected by various disorders (mainly intellectual disabilities) admitted to the Medical Genetics Unit, Gaslini Institute, Genoa, Italy, between January 2008 and December 2015, and their healthy parents for a total of 600 control individuals with no clinically evident pectoralis muscle abnormalities nor other features usually reported to be associated with PS.Table 1Summary of clinical data of all 120 patientsClinical featureTotal patients 120Gender Females44 Males76Pectoralis major muscle features Agenesis51 Hypoplasia69 Right-sided71  Males44  Females27 Left-sided49  Males33  Females16 Isolated form42 With associated anomalies78Associated anomalies Pectus excavatum/carinatum21 Rib anomalies10 Clavicle defects1 Vertebral defects1 Craniosynostosis1 Upper limb anomalies57 Classic brachysyndactyly24 Hypoplasia of upper limb and/or hand28Cerebellar malformations and intellectual disabilities1Poland-Möbius syndrome1

All patients were evaluated by a multidisciplinary team enclosing surgeons, radiologists, orthopaedic surgeons, and clinical geneticists to get a complete evaluation of the patient phenotype. The presence of additional anomalies as dysmorphic signs, and the presence of associated syndromic features were carefully evaluated by a team of clinical geneticists with experience in dysmorphology. PS specific features and the possible presence of additional anomalies were investigated in details by physical examination, followed by radiological/ultrasound examination.

Karyotyping and array-CGH analyses {#Sec4}
----------------------------------

Chromosome analysis was carried out on GTG-banded chromosomes at a resolution of 550 bands. Array-CGH analysis was performed using a genomic oligonucleotide-array with 13 kb (AMADID 022060) or 22 kb (AMADID 014698) (Human Genome Microarray Chip; Agilent Technologies, Palo Alto, CA, USA). Array data were analyzed using the Agilent Genomic Workbench Lite Edition Software 6.5.0.18. Aberration segments were reviewed using GRCh37 hg19 of UCSC Genome Browser (<http://genome.ucsc.edu/index.html>). We annotated all detected copy number variations (CNVs) and CNV-encompassed genes across public databases: Genomic Variants Database (DGV) (<http://dgv.tcag.ca/dgv/app/home>), DECIPHER (<https://decipher.sanger.ac.uk/>), Clinical Genome Resource (ClinGen) and ISCA ([http://www.clinicalgenome.org](http://www.clinicalgenome.org/)), OMIM ([http://www.omim.org](http://www.omim.org/)), PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), and databases of mouse (MGD)([http://www.informatics.jax.org](http://www.informatics.jax.org/)) and zebrafish (ZFIN) (ZFIN, [http://zfin.org](http://zfin.org/)) models.

CNV annotation {#Sec5}
--------------

All detected CNVs were tested for inheritance by hybridization of the parental DNA with the same array platform. A CNV was classified as unreported if it differed from those already reported for involving one more gene and/or if it differed by at least 100 kb on either side or by a total of 100 kb on both sides. To assess the clinical significance of the detected CNVs, we followed the recommended steps from Miller and coll. \[[@CR15]\]. All imbalances classified as benign in the ClinGen and/or found in our internal database of healthy individuals were considered to be benign and excluded from further analysis. The remaining CNVs were classified into groups. Group I contains genomic imbalances classified as being variants of uncertain clinical significance (VOUS) because of their unclear possible pathogenicity. CNVs were further classified as VOUS likely pathogenic, if including genes with a possible correlation to the phenotype, or simply VOUS, those CNVs for which clinical interpretation remains uncertain. Group II contains pathogenic CNVs overlapping critical regions of known microdeletions or microduplications and/or involving genes already described as causing a phenotype. These CNVs are found in the publicly available DECIPHER (<https://decipher.sanger.ac.uk/>) and ISCA ([www.clinicalgenome.org](http://www.clinicalgenome.org/)) databases and in published literature. Only VOUS, and VOUS likely pathogenic variants were further investigated.

Real-Time genomic qPCR {#Sec6}
----------------------

Validation by an independent assay, i.e. quantitative polymerase chain reaction (qPCR), was obtained for de novo and/or unreported CNVs identified in PS patients (Additional file [1](#MOESM1){ref-type="media"}) according to established protocols \[[@CR16]\]. Briefly, DNA from the patients was analyzed together with DNA from one healthy adult used as control. Primers were designed to amplify a region lying inside the deletion or duplication and one region flanking the CNV. A region on chromosome 12 encompassing the *GAPDH* gene (NM_002046.3) was used as internal control to determine copy number and normalize primer efficiency (primer sequences are available on request). qPCR was performed using the iCycler (Biorad, Hercules, CA) with Sybr Green, and the comparative DDCt method as previously described \[[@CR16], [@CR17]\].

Bioinformatics and network analysis of genes included within CNVs {#Sec7}
-----------------------------------------------------------------

We searched for mutations affecting the identified CNV-genes, and possibly associated to genetic disorders and/or anomalous phenotype, through available public databases: OMIM, PubMed, UCSC, GeneCard (<http://www.genecards.org/>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>).

We used GeneCodis3 \[[@CR18]\] to unveil enrichment of annotations. Genomic coordinates of altered regions were used to retrieve CNV overlapping genes from the hg19 RefSeq track of the UCSC genome browser. All the genes obtained from either duplicated or deleted regions were used as input in GeneCodis (Additional file [2](#MOESM2){ref-type="media"}). This tool allows the classification of genes according to their putative biological function by screening the Gene Ontology (GO), OMIM, Panther Pathway, and KEGG Pathway. In the analysis, the hypergeometric test was applied followed by the false discovery rate correction (FDR) with a cut-off of 5% to determine which annotations were significantly enriched. For GO analysis, various hierarchical levels of the annotation data structure were used. A graphical representation of the GeneCodis analysis results and of the possible interrelationship among the CNV-genes was obtained by using Cytoscape tool \[[@CR19]\].

Results {#Sec8}
=======

Clinical phenotypes {#Sec9}
-------------------

Clinical data from 120 sporadic PS patients, 115 new and 5 already reported \[[@CR1], [@CR8], [@CR9]\] were collected and their clinical features summarised in Table [1](#Tab1){ref-type="table"}. Rarely, PS patients can show associated anomalies involving other structures/organs \[[@CR20]\]. Overall, no dysmorphic signs or other anomalies were observed in these patients but one, who presented with associated Möbius syndrome features. This patient was referred to the Medical Genetics Unit of Istituto Gaslini Genoa at the age of 9 months showing the following anomalies: weight and head circumference \< 3^rd^ centile; length at 5^th^ centile; right facial nerve paralysis; epicanthic folds; micrognatia and cleft palate (Pierre Robin sequence, MIM261800); right abducens nerve paralysis; right auditory nerve paralysis; right upper limb hypoplasia; flexion deformity of the left elbow and the left wrist.

Genomic rearrangements identified in Poland syndrome patients {#Sec10}
-------------------------------------------------------------

Karyotyping and array-CGH analyses were performed in all patients. This survey led to the identification of 14 different heterozygous chromosome anomalies in 14 different patients, notably the same alteration was never reported in more than one patient (Table [2](#Tab2){ref-type="table"}). The duplication of patient PS14 and the deletion of patient PS15 overlapped the same 1.8Mbp region on chromosome 16p13.1 causing a dosage imbalance of the same 12 RefSeq genes. Smaller deletions affecting chromosome 16p13.1 were found in two in-house controls, and chromosome 16p13.1 deletions and 16p13.1 duplications were reported in patients with intellectual disabilities \[[@CR21]\] and autism \[[@CR22]\], respectively, without any PS-associated clinical sign. Except for CNVs involving chromosome 16p13.1 region, CNV data of PS patients and in-house controls did not reveal any shared CNVs. The deletion of patient PS6 overlaps the *AUTS2* gene, a susceptibility candidate gene for autism that is not related to PS-involved tissues.Table 2Genomic deletions and duplications detected in 19 patients with Poland syndromePatients IDGenderChr. bandCoordinates Hg19Size (Mbp)CNVPossible candidate genes^a^InhPectoralis muscle phenotype (L/R)/Additional anomalies (L/R)Previous reports2F5p15.2chr5:13266637-140115800.74Dup*DNAH5, TRIO*Mathypoplasia (L)/upper limb hypoplasia (L)-3M5p14.3chr5:22187485-227402870.55Dup*CDH12*de novohypoplasia (R)/hand hypoplasia (R)-4^b^F5p14.1-p13.3chr5:27656463-296508021.99Del*CDH6, CDH9*Mathypoplasia (R)-5M6q21-q22.1chr6:111777947-1164880074.71Del*REV3L, FYN, WISP3, LAMA4, MARCKS, FRK, COL10A1*Ndhypoplasia (R)/scoliosis/pectus excavatum/intellectual disability(22)6F7q11.22chr7:70182803-702237370.04Del*-*de novoagenesis (L)/brachysyndactyly (L)/ASD, pectus excavatum-7F9p24.2-p24.1chr9:4152060-46276240.48Dup*GLIS3*Matagenesis (L)/upper limb hypoplasia (L)-9F11q12.3chr11:63185662-633423690.16Del*HRASLS5, RARRES3, HRASLS2, PLA2G16*de novohypoplasia (R)/hand hypoplaisa, vertebral defects(8)10M11p14.1chr11:28131098-283497120.22Del*KIF18A*Mathypoplasia (R)-11F12q21.31-q21.32chr12:86018191-874326561.41Dup*NTS*Pathypoplasia (R)/brachydactyly-12M13q12.11-q12.12chr13:22840054-248901432.05Del*SGCG, SACS, SPATA13*Matagenesis (R)/brachysyndactyly (R), pectus excavatum-14F16p13.11-p12.3chr16:15256686-185467593.29Dup*NDE1, MYH11, ABCC6, XYLT1*Not matagenesis (R)/upper limb hypoplasia (R)-15M16p13.11-p12.3chr16:15131723-163057361.17Del*RRN3, NDE1, MYH11, ABCC6*Ndhypoplasia (R), pectus carinatum-16F16q22.3-q23.1chr16:74087653-745197240.43Dup*PSMD7, GLG1*Matagenesis (L)/upper limb hypoplasia (L), rib defects(1)20MXp11.22chrX:53666883-540566730.39Dup*HUWE1*Mathypoplasia (R)(1)^a^Genes previously implicated in: muscle/limb/skeletal structure and/or development; blood vessel structure and/or development; cell junction organization; cell division. ^b^In this case the deletion does not encompass any genes, however, since it overlaps 5′ regions of two genes, *CDH6, CDH9*, these genes were both enclosed in this table as their expression could be impaired by the deletion. Inh = inheritance

The parental origin was assessed for 11 of identified CNVs: 3 occurred *de novo*, eight were inherited from a healthy parent (seven maternal, one paternal). Clinical evaluation excluded the presence of any thoracic anomalies in the parents of all PS patients, indeed, the parents of patients PS11 and PS12, suspected to present a slight form of pectoralis muscle hypoplasia, were further examined by ultrasound analysis that confirmed a normal phenotype for all of them.

One patient (PS2) carried a duplication, dup(5)(p15.2), resulting from translocation 46, XX, t(5;11)(p15.1;q21) inherited from his unaffected mother. This was the only chromosome anomaly identified by standard karyotyping, one additional PS patient presented with 47,XXY karyotype associated with Klinefleter syndrome. Of the fourteen identified anomalies, except for 16p13.11-p12.3 deletion and duplication in patient PS14 and PS15 respectively, 12 were not present in DGV or differed from the reported CNVs by at least 100 kbp and/or involved at least one more gene. No newly identified CNVs matched those reported in DECIPHER or ClinGen.

Annotation of genes within CNVs {#Sec11}
-------------------------------

Based on the RefSeq database, 119 genes were identified in either duplicated or deleted regions (CNV-genes), including CNV-encompassed genes, genes interrupted by CNVs, and the two genes flanking CNVs on both sides. These last genes were included in the study according to the hypothesis that CNVs could impair their expression by removing or duplicating or separating expression regulatory elements from the coding sequences (Additional file [2](#MOESM2){ref-type="media"}). We investigated each CNV-gene for mutations associated to known disorder and/or anomalous phenotype through the use of available public genetic databases. Only one gene, *REV3L*, resulted to be recently described as associated to one patient with PS features \[[@CR23]\]. Thirteen genes were known disease genes reported in OMIM.

To gain further insight into the deleterious effects of mutations involving all CNV-genes, we performed a complete analysis of phenotypes resulting from inactivation of CNV-gene murine and zebrafish orthologs. For 34 genes, at least one murine mutant has been reported and phenotypically characterized. Most reported mouse mutants presented defects in tissues different from those affected in PS. For each patient, CNV-genes that could be considered as PS candidate genes on the basis of their expression pattern or molecular function are showed in Table [2](#Tab2){ref-type="table"}.

Bioinformatic analysis of genes included within CNVs {#Sec12}
----------------------------------------------------

All CNV-genes were analyzed by GeneCodis to search for a significant enrichment of annotations, which can be used as functional descriptor of the biological processes involved in PS. Sixty-one of the total genes were annotated using GeneCodis, unmapped genes consisted of poorly annotated non-coding RNAs. We identified significant enrichment of 8 biological categories (Table [3](#Tab3){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}), some of them, as those concerning mechanisms of chondrocyte and/or skeletal muscle development, blood coagulation, and DNA binding and apoptotic processes, relevant as candidate mechanisms contributing to PS development.Table 3Biological processes associated with genes rearranged in patients with PSGenesAnnotationsList size^a^Reference Support^b^Reference size^c^Hyp_c^d^FYN, CDH6, CDH9, FRK, CDH12Panther P00012: Cadherin signaling pathway (modular enrichment)61140342087.40x10^-5^FYN, TRIO, KIF18A, MYH11, FRK, TUBE1, ABCC6, KIAA0430, REV3L, DNAH5, ABCC1GO 0000166: nucleotide binding (MF) (modular enrichment)612120342083.70x10^-3^CDH6,HDAC2, CDH9,CDH12Panther P00057: Wnt signaling pathway (modular enrichment)61280342084.05x10^-3^FYN, KIF18A, HDAC2GO 0005515: protein binding (MF); GO 0007596: blood coagulation (BP) (modular enrichment)61251342081.92x10^-2^TRIO, LGALS12, PSMD7, TNFRSF19GO:0006915, apoptotic process (BP) (modular enrichment)61594342083.02x10^-2^KIF18A, TUBE1, DNAH5GO 0007018, microtubule-based movement (BP)6190342082.88x10^-2^GLG1GO 0032330: regulation of chondrocyte differentiation (BP)613342084.17x10^-2^MYH11GO 0030241, skeletal muscle myosin thick filament assembly (BP)613342084.17x10^-2^*Abbreviations*: ^a^Total number of genes in the input CNV list. ^b^Number of annotated genes in the reference list. ^c^Total number of genes in the reference list. ^d^Hyp_c = Corrected hypergeometric pValue using FDR procedure with a cut-off of 5% GeneCodis. BP = biological processes. MF = molecular function Fig. 1Graphical representation of the possible interrelationship among the CNV-genes. In this figure, CNV-genes (*light blue rounded nodes*) and enriched categories (*green diamonds*) identified by GeneCodis analysis and their possible relantionships are visualized by Cytoscape tool

Discussion {#Sec13}
==========

Here we present the first comprehensive survey of CNVs in PS and provide a catalog of CNVs and candidate genes possibly implicated in the PS phenotype. Most of the novel rearrangements identified in this study were transmitted from unaffected parents. This is expected on the basis of incomplete penetrance observed in familial cases \[[@CR1]\] and indicates that these CNVs may act as susceptibility alleles rather than direct causes of PS. In our cohort of patients, CNVs involved different genomic regions and different genes, which indicates that each identified CNV can account for single specific cases. This lack of overlap can be due to a sampling issue, or one may hypothesize that, if more than one CNV is related to the disease, the genes involved in these CNVs are members of the same family and/or belong to the same pathways. To unveil possible interplays among identified CNV-genes, we performed a comprehensive bioinformatic analysis of CNVs identified in our patients (Tab. [2](#Tab2){ref-type="table"}). This analysis showed significant enrichment of proteins involved in cell adhesion, blood coagulation, chondrogenesis, asymmetric development, skeletal muscle structure, and nucleotide binding (Table [3](#Tab3){ref-type="table"}). For each category and/or according to their expression pattern and function, we present the most relevant genes based on their hypothetical role in PS. The complete lack of *LAMA4* caused in mice hemorrhages associated with capillary defects, adipose tissue alteration, and motor control impairment \[[@CR24], [@CR25]\]. These findings suggest that the deletion of *LAMA4*, by inducing hemorrhages during embryonic development, could cause a variety of defects, possibly including those observed in PS patients. This hypothesis is in line with that of disruption of blood supply during development as causative of PS \[[@CR5], [@CR6]\]. The *MYH11* gene, encoding the contractile protein myosin, was found duplicated in patient PS14 and deleted in patient PS15, suggesting it could be a dosage-sensitive gene. *MYH11* missense mutations cause a dominant form of thoracic aortic aneurysm and/or aortic dissection (AAT4, MIM132900) and *Myh11* null mice exhibit dilated cardiomyopathy \[[@CR26]\]. No pectoralis muscle anomalies nor PS-associated bone defects have been reported in AAT4 patients or described in *Myh11* null mice. In our study, the cadherin signaling pathway resulted as the most significant among all analyzed categories and, notably, the *CDH12* spanned the breakpoint of a duplication originating de novo in one patient. Neither hereditary disease nor animal models are known for *CDH12. Glg1* null mice were found to die shortly after birth and about 30% of the few surviving mice had bone defects \[[@CR27]\]. Patients with deletion of *DNAH5* exhibit randomization of left-right body asymmetry as situs inversus, or partial transposition of the viscera as isolated dextrocardia. Asymmetry is also a major feature of PS and the combination of PS and isolated dextrocardia was described in 11% of PS patients \[[@CR28]\]. *DNAH5* was duplicated in patient PS2 who presented asymmetric development of pectoralis muscles and upper limbs, although without dextrocardia. No data have been reported on the effects of enhanced *DNAH5* expression, for instance due to gene duplication, so we cannot exclude that both mechanisms, i.e. deficiency as well as enhancement of *DNAH5* function, may induce asymmetric development. Asymmetric development was also observed in mice carrying inactivation of the *Rrn3* gene \[[@CR29]\]. The *SGCG* gene is associated with a recessive form of limb-girdle muscular dystrophy (LGMD2C, MIM253700). Of note, both PS and LGMD2C affect muscles of the limb-girdle.

An attractive candidate gene is *TRIO,* whose complete absence in mice causes embryonic lethality associated with abnormal development of skeletal muscle and neural tissues. Indeed, *Trio* deficiency caused a specific defect of myogenesis resulting in anomalies of skeletal muscle formation \[[@CR30]\].

In fact, after consulting available genetic databases, OMIM, and PubMed, no mutations in any of the above mentioned genes have been previously reported as causing a phenotype resembling that showed by PS patients, except for one, the *REV3L* gene \[[@CR23]\].

Mutations in the *REV3L* gene have been recently associated with Möbius syndrome (MBS) \[[@CR23]\], a rare congenital cranial dysinnervation disorder characterized by facial palsy and variable other congenital anomalies, including pectoralis muscle hypoplasia. Thomas-Roca and collaborators showed that mutations in *REV3L* are responsible for a proportion of MBS patients with highly variable clinical features and no obvious genotype--phenotype correlations. Accordingly, the pectoralis muscle agenesis was observed in only one among the three MBS patients carrying heterozygous *REV3L* mutations \[[@CR23]\]. The *REV3L* gene encodes a protein acting as catalytic subunit of DNA polymerase z, an error-prone DNA polymerase with a key role in replication of damaged DNA \[[@CR31], [@CR32]\]. In the absence of *REV3L* \[[@CR33]\], unrepaired DNA damage triggers apoptosis via the accumulation of double-stranded DNA breaks. To explain the variability of phenotypes associated to the identified *REV3L* mutations in the MBS, Thomas-Roca and collaborators hypothesized that *REV3L* deficiency may result in a stochastic ablation of cell lineages during embryonic development, caused by replicative stress at endogenous DNA lesions and consequent DNA damage responses. According to this hypothesis, the appearance of the described PS-MBS associated phenotype in one *REV3L* mutation carrier may represent a very rare stochastic event. The description of a case carrying a deletion affecting the *REV3L* gene and showing a complex phenotype including PS without any apparent MBS signs (patient PS5) may support the hypothesis of mechanisms leading *REV3L* mutations to cause variable phenotypes but also seems to support a direct role of *REV3L* gene in pectoralis muscle development.

Conclusion {#Sec14}
==========

Data obtained by standard karyotype and array-CGH analyses in our cohort of 120 patients suggest that chromosome anomalies, duplications and deletions, are a rare cause of PS. Most of identified CNVs are inherited by unaffected parents, thus suggesting they could act as modifiers and represent risk factors of PS. Genes overlapped by the identified CNVs are enriched in functional categories and pathways involved in cell-cell adhesion, DNA binding and apoptosis processes, suggesting these processes as playing a role in PS development and indicating the identified genes as candidates for further evaluation in functional studies or mutation screening in other patients by direct sequencing or exome sequencing.

Additional files {#Sec15}
================

Additional file 1:**Figure S1.** Quantitative polymerase chain reaction. In the Figure, examples of qPCR results obtained from three PS patients carrying three different CNVs are shown. A) Patient PS16: primers were designed to amplify a region encompassed by the duplication (chr16:74,313,856-74,313,966) and a 5′ flanking region (chr16:73,857,457-73,857,556); B) patient PS3: primers were designed to amplify a region encompassed by the duplication (chr5:22,539,039-22,539,170) and a 5′ flanking region (chr5:21,756,984-21,757,122); C) Patient PS10: primers were designed to amplify a region encompassed by the deletion (chr11:28,126,119-28,126,268) and a 5′ flanking region (chr11:28,075,866-28,076,003). Fold change of about 1 is expected for a diploid sample, about 0.5 for a haploid sample, and about 2.0 for a triploid sample. ctr: genomic DNA from one healthy adult used as control. (TIF 1168 kb) Additional file 2:**Table S2.** Annotated CNV-genes of PS patients. DUP = gene encompassed by a duplication; DEL = gene encompassed by a deletion; CNV-flanking gene = gene flanking a CNV; DUP-INTERRUPT = gene overlapping a duplication breakpoint. (DOCX 17.5 kb)
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:   Array-comparative genomic hybridization
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